SG11201408047XA - Macrocyclic inhibitors of flaviviridae viruses - Google Patents
Macrocyclic inhibitors of flaviviridae virusesInfo
- Publication number
- SG11201408047XA SG11201408047XA SG11201408047XA SG11201408047XA SG11201408047XA SG 11201408047X A SG11201408047X A SG 11201408047XA SG 11201408047X A SG11201408047X A SG 11201408047XA SG 11201408047X A SG11201408047X A SG 11201408047XA SG 11201408047X A SG11201408047X A SG 11201408047XA
- Authority
- SG
- Singapore
- Prior art keywords
- california
- foster city
- gilead sciences
- lakeside drive
- lllll
- Prior art date
Links
- 241000710781 Flaviviridae Species 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 229940126656 GS-4224 Drugs 0.000 abstract 15
- 150000001875 compounds Chemical class 0.000 abstract 2
- 102220240796 rs553605556 Human genes 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- NRUQNUIWEUZVLI-UHFFFAOYSA-O diethanolammonium nitrate Chemical compound [O-][N+]([O-])=O.OCC[NH2+]CCO NRUQNUIWEUZVLI-UHFFFAOYSA-O 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 208000006454 hepatitis Diseases 0.000 abstract 1
- 231100000283 hepatitis Toxicity 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/504—Pyridazines; Hydrogenated pyridazines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
- C07K5/06052—Val-amino acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06086—Dipeptides with the first amino acid being basic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Zoology (AREA)
- Child & Adolescent Psychology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261657550P | 2012-06-08 | 2012-06-08 | |
| PCT/US2013/044826 WO2013185103A1 (en) | 2012-06-08 | 2013-06-07 | Macrocyclic inhibitors of flaviviridae viruses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201408047XA true SG11201408047XA (en) | 2015-01-29 |
Family
ID=48692655
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201408047XA SG11201408047XA (en) | 2012-06-08 | 2013-06-07 | Macrocyclic inhibitors of flaviviridae viruses |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US9145441B2 (pm) |
| EP (1) | EP2861604B1 (pm) |
| JP (1) | JP6209601B2 (pm) |
| KR (1) | KR20150040265A (pm) |
| CN (1) | CN104703991B (pm) |
| AU (1) | AU2013270672B2 (pm) |
| BR (1) | BR112014030630A2 (pm) |
| CA (1) | CA2875692A1 (pm) |
| EA (1) | EA026235B1 (pm) |
| ES (1) | ES2624223T3 (pm) |
| HK (1) | HK1211285A1 (pm) |
| IL (1) | IL236005A0 (pm) |
| IN (1) | IN2014MN02652A (pm) |
| MX (1) | MX2014014766A (pm) |
| NZ (2) | NZ703040A (pm) |
| PL (1) | PL2861604T3 (pm) |
| PT (1) | PT2861604T (pm) |
| SG (1) | SG11201408047XA (pm) |
| SI (1) | SI2861604T1 (pm) |
| WO (1) | WO2013185103A1 (pm) |
Families Citing this family (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2859009T3 (pl) | 2012-06-08 | 2018-03-30 | Gilead Sciences, Inc. | Makrocykliczne inhibitory wirusów flaviviridae |
| CN104703991B (zh) | 2012-06-08 | 2018-03-23 | 吉利德科学公司 | 黄病毒科病毒的大环抑制剂 |
| AR091279A1 (es) | 2012-06-08 | 2015-01-21 | Gilead Sciences Inc | Inhibidores macrociclicos de virus flaviviridae |
| SMT202100592T1 (it) | 2014-12-26 | 2021-11-12 | Univ Emory | Derivati antivirali della n4-idrossicitidina |
| LT3097102T (lt) | 2015-03-04 | 2018-01-25 | Gilead Sciences, Inc. | 4,6-diamino-pirido[3,2-d]pirimidino junginiai, moduliuojantys į toll panašius receptorius |
| US20170008785A1 (en) * | 2015-07-07 | 2017-01-12 | Nch Corporation | System and Method for Treating Water with a Biological Based Biocide |
| WO2017035230A1 (en) | 2015-08-26 | 2017-03-02 | Gilead Sciences, Inc. | Deuterated toll-like receptor modulators |
| CN109562107A (zh) | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的杂环降解决定子体 |
| CN109562113A (zh) | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的螺环降解决定子体 |
| EP3455219A4 (en) | 2016-05-10 | 2019-12-18 | C4 Therapeutics, Inc. | AMINE-RELATED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION |
| EP3455218A4 (en) | 2016-05-10 | 2019-12-18 | C4 Therapeutics, Inc. | C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION |
| BR102017010009A2 (pt) | 2016-05-27 | 2017-12-12 | Gilead Sciences, Inc. | Compounds for the treatment of hepatitis b virus infection |
| CA3025633C (en) | 2016-05-27 | 2021-02-23 | Gilead Sciences, Inc. | Methods for treating hepatitis b virus infections using ns5a, ns5b or ns3 inhibitors |
| JOP20190024A1 (ar) | 2016-08-26 | 2019-02-19 | Gilead Sciences Inc | مركبات بيروليزين بها استبدال واستخداماتها |
| MA46093A (fr) | 2016-09-02 | 2021-05-19 | Gilead Sciences Inc | Composés modulateurs du recepteur de type toll |
| US10640499B2 (en) | 2016-09-02 | 2020-05-05 | Gilead Sciences, Inc. | Toll like receptor modulator compounds |
| KR102305215B1 (ko) | 2016-10-14 | 2021-09-28 | 프리시젼 바이오사이언시스 인코포레이티드 | B형 간염 바이러스 게놈 내의 인식 서열에 대해 특이적인 조작된 메가뉴클레아제 |
| CN110234645A (zh) | 2017-01-25 | 2019-09-13 | 巴斯夫欧洲公司 | 制备卞型酰胺的方法 |
| AR110768A1 (es) | 2017-01-31 | 2019-05-02 | Gilead Sciences Inc | Formas cristalinas de tenofovir alafenamida |
| JOP20180008A1 (ar) | 2017-02-02 | 2019-01-30 | Gilead Sciences Inc | مركبات لعلاج إصابة بعدوى فيروس الالتهاب الكبدي b |
| EP3601267A1 (en) | 2017-03-21 | 2020-02-05 | Bayer Pharma Aktiengesellschaft | 2-methyl-quinazolines |
| JOP20180040A1 (ar) | 2017-04-20 | 2019-01-30 | Gilead Sciences Inc | مثبطات pd-1/pd-l1 |
| CN110769822A (zh) | 2017-06-20 | 2020-02-07 | C4医药公司 | 用于蛋白降解的n/o-连接的降解决定子和降解决定子体 |
| CN109384727B (zh) * | 2017-08-10 | 2023-07-28 | 中国科学院上海药物研究所 | 酞嗪酮类化合物、其制备方法、药物组合物及用途 |
| JP6934562B2 (ja) | 2017-08-22 | 2021-09-15 | ギリアード サイエンシーズ， インコーポレイテッド | 治療用複素環式化合物 |
| DK3706762T3 (da) | 2017-12-07 | 2024-12-16 | Univ Emory | N4-hydroxycytidin og derivater og antivirale anvendelser relateret dertil |
| LT3724190T (lt) | 2017-12-13 | 2022-10-10 | Lupin Limited | Pakeistieji bicikliniai heterocikliniai junginiai kaip prmt5 inhibitoriai |
| AU2018392213B2 (en) | 2017-12-20 | 2021-03-04 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3' cyclic dinucleotides with phosphonate bond activating the STING adaptor protein |
| KR102492115B1 (ko) | 2017-12-20 | 2023-01-27 | 인스티튜트 오브 오가닉 케미스트리 앤드 바이오케미스트리 에이에스 씨알 브이.브이.아이. | Sting 어댑터 단백질을 활성화하는 포스포네이트 결합을 가진 2'3' 사이클릭 다이뉴클레오티드 |
| KR102708681B1 (ko) | 2018-02-13 | 2024-09-26 | 길리애드 사이언시즈, 인코포레이티드 | Pd-1/pd-l1 억제제 |
| EP3759109B1 (en) | 2018-02-26 | 2023-08-30 | Gilead Sciences, Inc. | Substituted pyrrolizine compounds as hbv replication inhibitors |
| EP3774883A1 (en) | 2018-04-05 | 2021-02-17 | Gilead Sciences, Inc. | Antibodies and fragments thereof that bind hepatitis b virus protein x |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
| TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | ２，２，─環二核苷酸 |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| TW201945388A (zh) | 2018-04-12 | 2019-12-01 | 美商精密生物科學公司 | 對b型肝炎病毒基因體中之識別序列具有特異性之最佳化之經工程化巨核酸酶 |
| US20220274979A1 (en) | 2018-04-18 | 2022-09-01 | Bayer Pharma Aktiengesellschaft | 2-methyl-aza-quinazolines |
| WO2019204609A1 (en) | 2018-04-19 | 2019-10-24 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| WO2019211799A1 (en) | 2018-05-03 | 2019-11-07 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide |
| US11186579B2 (en) | 2018-07-06 | 2021-11-30 | Gilead Sciences, Inc. | Therapeutic heterocyclic compounds |
| AU2019297362B2 (en) | 2018-07-06 | 2022-05-26 | Gilead Sciences, Inc. | Therapeutic heterocyclic compounds |
| TWI809427B (zh) | 2018-07-13 | 2023-07-21 | 美商基利科學股份有限公司 | Pd‐1/pd‐l1抑制劑 |
| WO2020028097A1 (en) | 2018-08-01 | 2020-02-06 | Gilead Sciences, Inc. | Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid |
| AU2019366355B2 (en) | 2018-10-24 | 2022-10-13 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
| DK3873903T3 (da) | 2018-10-31 | 2024-04-02 | Gilead Sciences Inc | Substituerede 6-azabenzimidazolforbindelser som hpk1-hæmmere |
| CN112969505B (zh) | 2018-10-31 | 2023-11-14 | 吉利德科学公司 | 具有hpk1抑制活性的取代的6-氮杂苯并咪唑化合物 |
| KR102808642B1 (ko) | 2019-03-07 | 2025-05-14 | 인스티튜트 오브 오가닉 케미스트리 앤드 바이오케미스트리 에이에스 씨알 브이.브이.아이. | 3'3'-사이클릭 다이뉴클레오티드 및 이의 프로드럭 |
| JP7350871B2 (ja) | 2019-03-07 | 2023-09-26 | インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール，ヴイ．ヴイ．アイ． | ２’３’－環状ジヌクレオチドおよびそのプロドラッグ |
| EP3935065A1 (en) | 2019-03-07 | 2022-01-12 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
| TWI751516B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TW202212339A (zh) | 2019-04-17 | 2022-04-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| US11453681B2 (en) | 2019-05-23 | 2022-09-27 | Gilead Sciences, Inc. | Substituted eneoxindoles and uses thereof |
| CA3140708A1 (en) | 2019-06-18 | 2020-12-24 | Helen Horton | Combination of hepatitis b virus (hbv) vaccines and pyridopyrimidine derivatives |
| MY202182A (en) | 2019-06-25 | 2024-04-15 | Gilead Sciences Inc | Flt3l-fc fusion proteins and methods of use |
| US20220257619A1 (en) | 2019-07-18 | 2022-08-18 | Gilead Sciences, Inc. | Long-acting formulations of tenofovir alafenamide |
| WO2021034804A1 (en) | 2019-08-19 | 2021-02-25 | Gilead Sciences, Inc. | Pharmaceutical formulations of tenofovir alafenamide |
| AR120096A1 (es) | 2019-09-30 | 2022-02-02 | Gilead Sciences Inc | Vacunas para vhb y métodos de tratamiento de vhb |
| WO2021091956A1 (en) | 2019-11-04 | 2021-05-14 | Revolution Medicines, Inc. | Ras inhibitors |
| JP2022553857A (ja) * | 2019-11-04 | 2022-12-26 | レボリューション メディシンズ インコーポレイテッド | Ｒａｓ阻害剤 |
| JP2022553858A (ja) | 2019-11-04 | 2022-12-26 | レボリューション メディシンズ インコーポレイテッド | Ｒａｓ阻害剤 |
| ES3022990T3 (en) | 2019-12-06 | 2025-05-29 | Prec Biosciences Inc | Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome |
| TW202421168A (zh) | 2020-03-20 | 2024-06-01 | 美商基利科學股份有限公司 | 4’-c-經取代-2-鹵基-2’-去氧腺苷核苷之前藥及其製造與使用方法 |
| WO2021198981A1 (en) | 2020-04-01 | 2021-10-07 | Janssen Biopharma, Inc. | Antiviral compounds and uses thereof |
| MX2023001507A (es) | 2020-08-07 | 2023-03-06 | Gilead Sciences Inc | Profarmacos de analogos de nucleotidos de fosfonamida y su uso farmaceutico. |
| CA3194067A1 (en) | 2020-09-15 | 2022-03-24 | Revolution Medicines, Inc. | Ras inhibitors |
| CA3195519A1 (en) | 2020-09-18 | 2022-03-24 | Bayer Aktiengesellschaft | Pyrido[2,3-d]pyrimidin-4-amines as sos1 inhibitors |
| TWI815194B (zh) | 2020-10-22 | 2023-09-11 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
| EP4074317A1 (en) | 2021-04-14 | 2022-10-19 | Bayer AG | Phosphorus derivatives as novel sos1 inhibitors |
| PE20240089A1 (es) | 2021-05-05 | 2024-01-16 | Revolution Medicines Inc | Inhibidores de ras para el tratamiento del cancer |
| KR20240006683A (ko) | 2021-05-13 | 2024-01-15 | 길리애드 사이언시즈, 인코포레이티드 | TLR8 조절 화합물과 항-HBV siRNA 치료제의 조합물 |
| KR20240023629A (ko) | 2021-06-23 | 2024-02-22 | 길리애드 사이언시즈, 인코포레이티드 | 디아실글리세롤 키나제 조절 화합물 |
| CA3222439A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| EP4359413A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| WO2022271677A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
| CN114634421A (zh) * | 2022-02-24 | 2022-06-17 | 济宁晟泰药业有限公司 | 一种达沙替尼中间体的制备方法 |
| JP7734874B2 (ja) | 2022-07-29 | 2025-09-05 | ファイザー・インク | 新規なａｃｃ阻害剤 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR006514A1 (es) | 1995-07-04 | 1999-09-08 | Sandoz Ag | Un macrolido, sus usos, un proceso para producirlo, un aislado biologicamente puro capaz de producirlo, y una composicion farmaceutica quelo comprende |
| US6124453A (en) | 1995-07-04 | 2000-09-26 | Novartis Ag | Macrolides |
| DE10239042A1 (de) | 2002-08-21 | 2004-03-04 | Schering Ag | Makrozyclische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel |
| US20050159345A1 (en) * | 2002-10-29 | 2005-07-21 | Boehringer Ingelheim International Gmbh | Composition for the treatment of infection by Flaviviridae viruses |
| NZ564326A (en) | 2005-06-16 | 2010-01-29 | Cv Therapeutics Inc | Prodrugs of A2B adenosine receptor antagonists |
| CA2611151A1 (en) * | 2005-06-17 | 2006-12-28 | Novartis Ag | Use of sanglifehrin in hcv |
| EP2011786A1 (en) | 2007-07-05 | 2009-01-07 | Laboratorios del Dr. Esteve S.A. | Indane-amine derivatives, their preparation and use as medicaments |
| CL2008003384A1 (es) | 2007-11-14 | 2009-12-11 | Enanta Pharm Inc | Compuestos derivados de quinoxalina macrocíclica, inhibidores de serina proteasa; composicion farmaceutica que los comprende; y su uso en el tratamiento de la hepatitis c. |
| BRPI0906946A2 (pt) | 2008-01-09 | 2015-07-14 | Univ Konkuk Ind Coop Corp | Vacinas baseadas em baculovírus |
| US20100080770A1 (en) * | 2008-09-29 | 2010-04-01 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| MX2011006764A (es) * | 2008-12-23 | 2011-08-03 | Ortho Mcneil Janssen Pharm | Procedimiento y compuestos intermedios para preparar un inhibidor de proteasa macrociclico del vhc. |
| EP2504315A1 (en) | 2009-11-23 | 2012-10-03 | Amgen Inc. | Amino heteroaryl compounds as beta-secretase modulators and methods of use |
| SG182475A1 (en) * | 2010-01-15 | 2012-08-30 | Gilead Sciences Inc | Inhibitors of flaviviridae viruses |
| US9227971B2 (en) | 2010-01-19 | 2016-01-05 | Merck Sharp & Dohme Corp. | Pyrazolo[1,5-a]pyrimidine compounds as mTOR inhibitors |
| WO2011098808A1 (en) * | 2010-02-09 | 2011-08-18 | Biotica Technology Limited | Sanglifehrin based compounds |
| GB201008123D0 (en) * | 2010-05-17 | 2010-06-30 | Biotica Tech Ltd | Novel compounds |
| US20130178413A1 (en) | 2010-09-21 | 2013-07-11 | John A. McCauley | Hcv ns3 protease inhibitors |
| AR084217A1 (es) * | 2010-12-10 | 2013-05-02 | Gilead Sciences Inc | Inhibidores macrociclicos de virus flaviviridae |
| AR091279A1 (es) | 2012-06-08 | 2015-01-21 | Gilead Sciences Inc | Inhibidores macrociclicos de virus flaviviridae |
| CN104703991B (zh) | 2012-06-08 | 2018-03-23 | 吉利德科学公司 | 黄病毒科病毒的大环抑制剂 |
| JP5989900B2 (ja) | 2012-06-08 | 2016-09-07 | グレンマーク ファーマシューティカルズ， エセ．アー． | ２−アミノ−４−アリールチアゾール化合物のアミド及びその塩類 |
| PL2859009T3 (pl) | 2012-06-08 | 2018-03-30 | Gilead Sciences, Inc. | Makrocykliczne inhibitory wirusów flaviviridae |
-
2013
- 2013-06-07 CN CN201380039194.XA patent/CN104703991B/zh not_active Expired - Fee Related
- 2013-06-07 BR BR112014030630A patent/BR112014030630A2/pt not_active Application Discontinuation
- 2013-06-07 IN IN2652MUN2014 patent/IN2014MN02652A/en unknown
- 2013-06-07 PT PT137312039T patent/PT2861604T/pt unknown
- 2013-06-07 NZ NZ703040A patent/NZ703040A/en not_active IP Right Cessation
- 2013-06-07 SI SI201330574A patent/SI2861604T1/sl unknown
- 2013-06-07 SG SG11201408047XA patent/SG11201408047XA/en unknown
- 2013-06-07 US US13/913,259 patent/US9145441B2/en not_active Ceased
- 2013-06-07 JP JP2015516260A patent/JP6209601B2/ja not_active Expired - Fee Related
- 2013-06-07 NZ NZ724503A patent/NZ724503A/en not_active IP Right Cessation
- 2013-06-07 WO PCT/US2013/044826 patent/WO2013185103A1/en active Application Filing
- 2013-06-07 HK HK15111999.1A patent/HK1211285A1/xx unknown
- 2013-06-07 ES ES13731203.9T patent/ES2624223T3/es active Active
- 2013-06-07 MX MX2014014766A patent/MX2014014766A/es unknown
- 2013-06-07 EP EP13731203.9A patent/EP2861604B1/en not_active Not-in-force
- 2013-06-07 CA CA2875692A patent/CA2875692A1/en not_active Abandoned
- 2013-06-07 AU AU2013270672A patent/AU2013270672B2/en not_active Ceased
- 2013-06-07 KR KR1020157000171A patent/KR20150040265A/ko not_active Withdrawn
- 2013-06-07 EA EA201492209A patent/EA026235B1/ru not_active IP Right Cessation
- 2013-06-07 PL PL13731203T patent/PL2861604T3/pl unknown
-
2014
- 2014-11-30 IL IL236005A patent/IL236005A0/en unknown
-
2015
- 2015-08-07 US US14/821,458 patent/US9512175B2/en not_active Expired - Fee Related
-
2017
- 2017-09-25 US US15/715,080 patent/USRE47334E1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| BR112014030630A2 (pt) | 2017-06-27 |
| CN104703991B (zh) | 2018-03-23 |
| JP6209601B2 (ja) | 2017-10-04 |
| AU2013270672B2 (en) | 2017-10-19 |
| PT2861604T (pt) | 2017-05-05 |
| WO2013185103A1 (en) | 2013-12-12 |
| IN2014MN02652A (pm) | 2015-08-21 |
| KR20150040265A (ko) | 2015-04-14 |
| US9145441B2 (en) | 2015-09-29 |
| JP2015518904A (ja) | 2015-07-06 |
| EA026235B1 (ru) | 2017-03-31 |
| USRE47334E1 (en) | 2019-04-02 |
| CN104703991A (zh) | 2015-06-10 |
| EP2861604A1 (en) | 2015-04-22 |
| AU2013270672A1 (en) | 2015-01-22 |
| US20150344521A1 (en) | 2015-12-03 |
| ES2624223T3 (es) | 2017-07-13 |
| EP2861604B1 (en) | 2017-03-01 |
| SI2861604T1 (sl) | 2017-05-31 |
| EA201492209A1 (ru) | 2015-05-29 |
| PL2861604T3 (pl) | 2017-08-31 |
| US9512175B2 (en) | 2016-12-06 |
| HK1211285A1 (en) | 2016-05-20 |
| NZ724503A (en) | 2017-12-22 |
| HK1209730A1 (en) | 2016-04-08 |
| IL236005A0 (en) | 2015-02-01 |
| US20140030221A1 (en) | 2014-01-30 |
| NZ703040A (en) | 2016-11-25 |
| MX2014014766A (es) | 2015-05-11 |
| CA2875692A1 (en) | 2013-12-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201408047XA (en) | Macrocyclic inhibitors of flaviviridae viruses | |
| SG11201408045UA (en) | MACROCYCLIC INHIBITORS OF <i>FLAVIVIRIDAE</i> VIRUSES | |
| SG11201408064PA (en) | Macrocyclic inhibitors of flaviviridae viruses | |
| SG11201407533SA (en) | Antiviral compounds | |
| SG11201900077QA (en) | 1,3-dihydroxy-phenyl derivatives useful as immunomodulators | |
| SG11201901700UA (en) | Biaryl compounds useful as immunomodulators | |
| SG11201408739VA (en) | Inhibitors of hepatitis c virus | |
| SG11201810983PA (en) | Novel heterocyclic derivatives useful as shp2 inhibitors | |
| SG11201908820VA (en) | Novel heterocyclic derivatives useful as shp2 inhibitors | |
| SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201407534PA (en) | New diazaspirocycloalkane and azaspirocycloalkane | |
| SG11201408791TA (en) | Dihydropyrimidine compounds and their application in pharmaceuticals | |
| SG11201804170RA (en) | Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders | |
| SG11201907889YA (en) | Glycan-interacting compounds and methods of use | |
| SG11201903835WA (en) | Antibodies directed against programmed death- 1 (pd-1) | |
| SG11201408261UA (en) | Syringe | |
| SG11201408279QA (en) | Social sharing of security information in a group | |
| SG11201408539UA (en) | Enhancing autophagy or increasing longevity by administration of urolithins or precursors thereof | |
| SG11201804152RA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201407115XA (en) | Carboxylic acid compounds | |
| SG11201900689RA (en) | Compounds and compositions and uses thereof | |
| SG11201408011SA (en) | Synthesis of antiviral compound | |
| SG11201407682TA (en) | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators | |
| SG11201907356SA (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
| SG11201408186TA (en) | Pyridinone and pyridazinone derivatives |